CD47 illustration: Shutterstock
August 26, 2024 10:30 AM EDT
R&D
In Focus

Once one of im­muno-on­col­o­gy's next great hopes, CD47 faces fi­nal shots on goal

Max Gelman

Senior Editor

Ear­li­er this sum­mer, a small biotech com­pa­ny’s read­out in what was once one of can­cer’s most in­trigu­ing ap­proach­es did lit­tle to set­tle the con­tro­ver­sy and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

NICE has 'done all we can' to ne­go­ti­ate for En­her­tu cov­er­age, reaf­firms de­ci­sion not to rec­om­mend

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times